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SYNOPSIS 
The finding of microscopic extranodal extension in any involved lymph nodes may elevate the 
risk of locoregional recurrence in patients with papillary thyroid carcinoma following curative 
total thyroidectomy, therapeutic neck dissection and radioactive iodine ablation. 
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ABSTRACT 
Background: 
The presence of microscopic extranodal extension (ENE) may increase locoregional recurrence 
(LRR) in papillary thyroid carcinoma (PTC). We aimed to evaluate the association between 
microscopic ENE, response to initial therapy and LRR risk following total thyroidectomy, 
therapeutic neck dissection and radioactive iodine (RAI) ablation in PTC. 
Methods: 
Of the 369 eligible PTC patients, 264 (71.5%) did not have microscopic ENE (group I) while 
105 (28.5%) did (group II). All presented with clinical nodal metastasis (cN1) and underwent 
therapeutic neck dissection and RAI ablation. Biochemical incompleteness meant post-ablation 
stimulated thyroglobulin (sTg) >10ng/mL. Multivariate analyses were conducted to identify 
independent factors for LRR. 
Results: 
Biochemical incompleteness was significantly more common group II (43.8% vs. 
17.4%,p<0.05). The 10-year locoregional free-survival was significantly worse in group II than I 
(52.0% vs. 86.2%, p=0.005). After adjusting for other significant factors, age<45 (p<0.05), 
multifocality (p<0.05), presence of ENE (p=0.027) were independent risk factors of LRR. The 
number and size of positive lymph nodes were not independent factors. 
Conclusions: 
Patients with microscopic ENE were significantly more likely to have biochemical 
incompleteness after initial therapy. After adjusting for other significant primary and nodal 
characteristics, microscopic ENE was an independent factor for LRR in patients with cN1. 
 
Keywords: Papillary thyroid carcinoma; nodal metastasis; distant metastasis; TNM staging; 
ATA risk stratification 
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma 
and its age-adjusted incidence has doubled in the last 25 years [1]. However, despite its excellent 
prognosis, locoregional recurrence (LRR) is common after curative surgery [2]. Cervical nodal 
metastasis (N1) is one of the most significant risk factors for LRR and studies have shown that in 
addition to N1, the nodal characteristics such as the number, size and ratio of positive lymph 
nodes (i.e. lymph node ratio or LNR) at surgery also carry prognostic significance [3-7]. In fact, 
under the new (2015) American Thyroid Association (ATA) guidelines, patients with N1 are 
stratified into one of three risk groups according to the total number and size of positive lymph 
nodes (LNs) retrieved at the initial surgery [8]. Under this newly-revised system, in the absence 
of other risk factors, a patient with ≤ 5 pathologic N1 micrometastasis (<0.2cm in largest 
dimension) would be in the low-risk group while a patient with >5 pathologic nodes with all 
involved LNs (<3cm in their largest dimension) would be in the intermediate-risk group. A 
patient with one or more involved LNs measuring ≥3cm in largest dimension would be classified 
as high-risk. 
However, despite this change, the modified ATA risk stratification system did not specifically 
include the presence of microscopic extra-nodal extension (ENE) as a factor for nodal risk 
stratification [8]. One reason for this omission is because it is believed that ENE is often tightly 
linked to other risk factors like the number of positive lymph nodes and extrathyroidal extension 
(ETE) of the primary tumor [8]. Furthermore, although gross or macroscopic ENE is known to 
predict poorer outcomes, microscopic ENE as an independent risk factor appears less certain 
especially when other inter-related risk factors like the number and size of positive LNs and 
extrathyroidal extension (ETE) of the primary tumor have been considered [8]. However, given 
the growing evidence showing the prognostic significance of ENE [9-11], we hypothesized 
microscopic ENE could be an independent risk factor for LRR. Therefore, our study aimed to 
evaluate the association between microscopic ENE and response to initial therapy as well as risk 
of LRR following a standardized total thyroidectomy, simultaneous therapeutic neck dissection 
and radioactive iodine (RAI) ablation. 
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PATIENTS AND METHODS 
From 1980 – 2011, 1915 consecutive PTC patients underwent surgery at our institution. Of 
these, 407 (21.3%) had simultaneous lateral N1 that was either clinically palpable or visible on 
preoperative ultrasound (USG) and later confirmed by fine needle aspiration cytology (FNAC) 
(i.e. clinical N1b or cN1b). Patients with distant metastasis (n=21), unresectable gross primary or 
nodal disease (n=3), ≤2 levels of lateral cervical nodes dissected (n=5) or gross extra-nodal 
invasion to surrounding structures (like the overlying sternocleidomastoid muscles, internal 
jugular vein, carotid artery or vagus nerve) at surgery (n=9) were excluded. Therefore, 369 
(20.3%) patients were eligible. Among these, 36 (9.8%) were follicular-variant, 3 (0.8%) were 
tall-cell variant and 6 (1.6%) were columnar-variant. All excised LN specimens were subjected 
to similar histological examination by our group of pathologists. Microscopic ENE was defined 
as the presence of tumor cells outside the capsule of a LN that harbored metastatic PTC (see 
Figure 1) without any evidence of macroscopic invasion to surrounding structures as judged by 
the operating surgeon. Based on microscopic examination of the harvested LNs, 264 (71.5%) 
patients were found not to have ENE (group I) while 105 (28.5%) patients were found to have 
ENE in at least one positive LN (group II). Relevant clinical, laboratory, radiologic, and 
perioperative data were collected prospectively and follow-up data were updated in a 
computerized database. Since this study spanned over a long period of time, initial tumor risk 
estimate and response to initial therapy (i.e. dynamic risk stratification) were retrospectively 
recoded according to the newly-revised ATA risk stratification system [8]. Clinicopathological 
features (including number, size of positive LNs and LNR), postoperative stimulated 
thyroglobulin (sTg), response to therapy and LRR were compared between the two groups. LNR 
(%) was defined as the number of metastatic LNs divided by the total number of LNs retrieved 
and multiplied by 100. 
Management of PTC 
Details of surgical treatment, criteria for radioactive iodine (RAI) ablation, postoperative and 
follow-up protocol had been described previously [12]. Total thyroidectomy and simultaneous 
therapeutic unilateral central (level VI) and lateral (levels II-V) selective neck dissections were 
performed for cN1b. Concomitant bilateral central dissection was only performed when there 
was clear evidence of disease within the central compartment. Two months after initial surgery, 
6 
 
an ablative RAI dose was given after LT4 withdrawal or with recombinant TSH. This was 
followed by the post-therapy scan 4-7 days later. sTg was defined as a Tg level measured when 
serum TSH >30 mIU/L either by 4-week thyroxine withdrawal or recombinant TSH injections. 
The pre-ablation sTg level was taken approximately 2-3 months after surgery (i.e. at the time of 
RAI ablation) while the post-ablation level was taken approximately 9-12 months after surgery 
(at the time of the diagnostic whole body scan (WBS)). Tg autoantibodies were measured at the 
same time. The decision for RAI ablation was based on the presence of 2 or more risk factors 
such as tumor size >1.5cm, N1, age >45 years old and extrathyroidal extension. TSH suppression 
to <0.1 ug/L was recommended for all patients with cN1. 
Postoperative and follow-up protocol 
All post-surgical patients were followed up within 4 weeks in a specialized combined oncology 
clinic. A follow-up visit was conducted at 6-month intervals in the first 2 years, 6 to 9-month in 
the subsequent 3 years and annually thereafter. Clinical examination, neck USG and non-
stimulated Tg level were done during follow-up visits. Response to initial therapy was assessed 
based on post-ablation sTg values obtained 9-12 months after surgery [8]. LRR was defined as 
an identifiable neck lesion on USG which was confirmed on FNAC and/or histology. 
Laboratory methods 
All postoperative sTg levels were measured at the same laboratory using the same immunometric 
assay. The assay used was the Immulite 2000 (Diagnostic Products Corp. Roche, Los Angeles, 
CA). This was calibrated against the CRM- 457 standard. Normal reference range was <0.5 – 55 
ug/L and sensitivity was <0.2 ug/L). 
Statistical analysis 
Statistical analysis was performed by chi-square or Fisher’s Exact test to compare categorical 
variables, and Mann-Whitney U or Kruskal-Wallis test was used to compare continuous 
variables between groups. Locoregional recurrence free survival (LRFS) was estimated using the 
Kaplan-Meier method and compared with log-rank test. Variables which were significant in the 
univariate analysis were entered into the multivariate analysis using Cox-regression analysis. All 
statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA). 
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RESULTS 
In our cohort, the majority (81.3%) had ipsilateral neck dissection while contralateral and 
bilateral selective neck dissections were performed in 9 (2.4%) and 60 (16.3%) patients, 
respectively. All patients had a minimum of levels II-IV nodes dissected with some (60.7%) also 
having level V nodes dissected at the same time. The total number of LNs (i.e. central + lateral 
compartments) harvested was 28.3 ± 19.3. Among this cohort, 95 (25.7%) did not have 
concomitant pN1a. All patients received radioiodine (RAI) ablation afterwards. 
Table 1 shows a comparison of clinicopathologic features, tumor stages, ATA risk stratification 
and MACIS score between group I and II. Age, histological variants and nodal stage were 
comparable between groups. Group II had significantly more males (41.0% vs. 26.1%,p=0.006), 
larger-sized tumors (2.8cm vs. 2.1cm,p=0.009), more extrathyroidal extension (80.0% vs. 
42.1%,p<0.001), higher T stage (40.0% vs. 14.8%,p<0.001), more high-risk tumors (31.4% vs. 
14.8%,p<0.001) and higher MACIS scores (6.4 vs. 5.4,p<0.001) than group I.  
Table 2 compares the number of harvested and positive LNs as well as size of largest positive 
LN between the two groups. Group II also had significantly more positive central (4.6 vs. 3.1, 
p=0.046) and lateral LNs (10.2 vs. 4.8, p<0.001). As a result, the overall number of positive LNs 
retrieved was significantly greater in group II (14.8 vs. 7.8, p<0.001) and the LNR was also 
significantly higher in group II (55.0% vs. 31.0%, p<0.001). The mean size of largest LN was 
also significantly larger in group II (26.7mm vs. 10.0mm, p<0.001). In our cohort, the smallest 
LN with ENE was 1.0cm and the lowest LNR with ENE was 9.6%. 
Table 3 compares postoperative sTg levels, adjuvant treatment, response to initial therapy and 
recurrences between the two groups. RAI dose, central uptake on WBS and ERT were 
comparable between the two groups. However, pre- and post-ablation sTg levels were 
significantly higher in group II than I (p<0.001). The proportion of undetectable post-ablation 
sTg (<0.5ug/L) was significantly lower in group II (17.1% vs. 36.4%, p<0.001). Similarly, the 
proportion of patients having an excellent response to therapy was significantly higher in group I 
(55.7% vs. 31.7%, p<0.001). The follow-up period was slightly shorter in group I than II 
(110.7months vs. 121.6 months, p=0.029) presumably because ENE occurred more commonly in 
the earlier study period.  
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After a mean follow-up of 113.8 ± 61.2 months, 78 patients developed LRR as their first site of 
recurrence and 27 patients eventually died of PTC. Among those who died, all were aged above 
64 years old at diagnosis. The most common first site of recurrence was the ipsilateral lateral 
compartment (n=63, 80.8%) followed by bilateral lateral compartments (n=9) and contralateral 
lateral compartment (n=6). No patient had isolated thyroid bed or central compartment 
recurrence. The mean size of recurrence was 1.5 ± 1.0cm and the number of patients with 
recurrence <1cm was 14 (17.9%). The 5- and 10-year LRFS were significantly worse in group II 
than I (60.7% vs. 88.4% and 52.0 vs. 86.2, p<0.001, respectively).  
Table 4 shows cox regression analyses for LRR. In the univariate analysis, younger age 
(p=0.026), larger tumor size (p<0.001), presence of ETE (p=0.039) and multicentricity 
(p=0.001), higher T stage (p=0.012), greater number of positive LNs (p=0.003), higher LN ratio 
(p<0.001), larger-sized nodal metastasis (p<0.001) and ENE (p<0.001) were significant risk 
factors of LRR. Given a large number of significant variables and the inter-related association 
between these variables, two multivariate analyses were performed. In the first model, tumor size 
and ETE were entered in place of T stage and number of positive LNs was entered in place of 
LNR. In this first model, younger age (p=0.004), larger-sized tumor (p=0.029), presence of 
multifocality (p=0.038) and presence of ENE (p=0.002) were independent factors for LRR. In 
the second model, T stage was entered in place of tumor size and ETE and LNR was entered in 
place of number of positive LNs. In this second model, younger age (p=0.004), presence of 
multifocality (p=0.043) and presence of ENE (p<0.001) were independent factors of LRR. In 
both model 1 and 2, when age<45 years old was entered as a categorical variable, it remained 
statistically significant (p<0.05). Therefore, age<45 years old, multifocality and ENE were 
independent factors for both models. 
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DISCUSSION 
Our data showed that patients with microscopic ENE in their excised LNs not only had 
significantly larger-sized tumors (p=0.009) but also locally more advanced primary tumors 
(p<0.001). Despite the successful RAI ablation in over 95% of the patients (as suggested by the 
very low percentage of central neck uptake on WBS), patients with ENE were less likely to have 
an excellent response to therapy (sTg <1ng/mL) than those without microscopic ENE (31.4% vs. 
55.7%, p<0.001, respectively). Furthermore, both the biochemical (sTg >10ng/mL) and 
structural incompleteness were significantly more common in patients with ENE (43.8% vs. 
17.4%, and 18.1% vs. 9,8%, respectively). Similar findings were reported by one study where 
the authors found the presence of ENE diminished the chance of biochemical completeness from 
49% to 21% (p=0.01) [10]. Although the exact reason for the higher biochemical incompleteness 
remains unclear, the most likely reason is because patients with ENE are generally at greater risk 
of having residual microscopic nodal disease leading to locoregional and/or distant failures [5,9]. 
Interestingly, our data clearly showed that of the 4 nodal characteristics (i.e. number, size of 
positive LNs, LNR and ENE), the presence of microscopic ENE was a single most significant 
determinant of LRR in patients with cN1. In fact, ENE was the only independent nodal 
characteristic that was significant in both multivariate models along with younger age and 
presence of multifocality (see Table 4). In contrast to previous studies [4,13], our data did not 
show the number, size of positive LNs or LNR to be independent factors for LRR. However, 
given the significant inter-related association between these variables and the presence of ENE 
(see Table 2), it is possible that the dominant effect of ENE may diminish the effect of other 
factors. Nevertheless, this implies that of the 4 nodal characteristics, ENE may have the greatest 
prognostic significance on LRR.  
It is worth noting that although none of the three significant factors (i.e. age, multifocality and 
ENE) were included in the latest ATA risk stratification system, age and multifocality had 
certainly been incorporated in other risk stratification systems from the Latin American Thyroid 
Society and the European Consensus Conference, respectively [14,15]. Furthermore, a recent 
meta-analysis has reported that multifocality is significantly associated with an increased risk of 
nodal metastases and persistent / recurrent disease [16] 
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Given that all of our patients already underwent a complete thyroidectomy and an adequate (≥3 
levels) neck dissection in the involved lateral compartment, the implications are first, relative to 
those without ENE, patients with ENE should be placed under a more intense surveillance for 
possible LRR. Although over 40% of our patients with ENE developed LRR, this appeared 
comparable to other similar series [9,10]. Since over 80% of LRR were found in the ipsilateral 
lateral compartment, special attention should be paid to this area during USG screening. Our data 
showed that recurrence in the contralateral lateral compartment was very uncommon (7.7%). 
Second, given the higher chance of residual microscopic disease (as reflected by the higher rate 
of biochemical and structural incompleteness), patients with ENE may benefit from a higher 
dose of RAI ablation in an attempt of completely ablating any residual microscopic disease. 
However, only a prospective study would be able to confirm this postulation. 
Despite our findings, we would acknowledge certain shortcomings. First, we only evaluated the 
prognostic significance of microscopic ENE and since this is usually not apparent until after 
surgery, our study findings are unlikely to change the initial surgical strategy/plan. Nevertheless, 
it is conceivable that patients with macroscopic ENE would be at an even greater risk of LRR. 
Second, our analysis did not specifically analyze the extent of ENE or the number of nodes 
having ENE. Similar to the first point, those with greater extent of microscopic ENE or number 
of involved nodes with ENE are probably at greater risk of LRR than those with limited ENE 
involvement. Third, since we did not divide the entire nodal specimen into different levels, it was 
not possible to tell whether the site of recurrence was positive or had ENE at the first operation. 
This information would have enhanced our understanding on the pattern of nodal recurrence in 
patients with ENE. Fourth, since this was a retrospective analysis, our study was prone to 
selection biases. However, it would have taken a great deal amount of time and effort to conduct 
a similar study prospectively. 
Conclusion 
Patients with microscopic ENE in their excised LNs not only had significantly larger and locally 
more advanced primary tumors but were also less likely to have an excellent response to initial 
therapy (defined as sTg <1ng/mL) than those without ENE. After adjusting for other significant 
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primary and nodal characteristics, ENE remained an independent factor for LRR in patients with 
cN1. 
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FIGURE LEGEND 
Figure 1. A high-power view showing the presence of tumor cells outside the capsule of a lymph 
node that harbored metastatic papillary thyroid carcinoma. The black arrows outline the original 
lymph node capsule. 
 
 
Table 1. A comparison of clinicopathological features, tumor and nodal stages, ATA risk 
stratification and MACIS scores between those without extra-nodal extension (ENE) (Group I) 
and those with ENE (Group II) 
 Group I (n=264) Group II (n=105) p-value 
Age at operation (years) 49.35 ± 20.44 52.14 ± 20.39 0.211 
Sex 
- Male  
- Female 
 
69 (26.1) 
195 (73.9) 
 
43 (41.0) 
62 (59.0) 
0.006 
Type of papillary carcinoma variants 
- Classic 
- Follicular 
- Tall 
- Columnar 
 
240 (90.9) 
18 (6.8) 
3 (1.1) 
3 (1.1) 
 
84 (80.0) 
15 (14.3) 
0 (0.0) 
3 (2.9) 
0.241 
Tumor size (cm) 
-     Mean ± SD 
- ≤ 2  
- ≤ 4 
- >4 
 
2.12 ± 1.53 
156 (59.1) 
81 (30.7) 
27 (10.2) 
 
2.75 ± 1.92 
54 (51.4) 
36 (34.3) 
15 (14.3) 
 
0.009 
0.338 
Extrathyroidal extension 
- None 
- Minimal  
 
153 (58.0) 
72 (27.3) 
 
21 (20.0) 
42 (40.0) 
<0.001 
- Macroscopic  39 (14.8) 42 (40.0) 
Multifocality 166 (62.9) 69 (65.7) 0.671 
Tumor stage* 
- T1  
- T2 
- T3  
- T4 
 
105 (39.8) 
48 (18.2) 
72 (27.3) 
39 (14.8) 
 
15 (14.3) 
6 (5.7) 
42 (40.0) 
42 (40.0) 
<0.001 
Nodal staging* 
- N1b 
- N1a & N1b 
 
71 (27.0) 
193 (73.1) 
 
24 (22.9) 
81 (77.1) 
0.424 
ATA initial risk stratification# 
- Intermediate 
- High 
 
225 (85.2) 
39 (14.8) 
 
72 (68.6) 
33 (31.4) 
<0.001 
MACIS score 5.44 ± 2.20 6.40 ± 2.31 <0.001 
Categorical variables are expressed as number (percentage) 
Abbreviations: ATA = American Thyroid Association; MACIS = Metastases, Age, 
Completeness of surgery, Invasion and Size 
*Based on the 7th edition Tumor, Node and Metastasis pathological staging system 
#according to the 2015 modified ATA risk stratification [8] 
 
Table 2. A comparison of number of lymph nodes (LNs) harvested, number of positive LNs and 
size of the largest positive LN between those without extra-nodal extension (ENE) (Group I) and 
those with ENE (Group II) 
 Group I (n=264) Group II (n=105) p-value 
Central compartment (level IV) 
- Total no. of  LNs harvested 
- Total no. of positive LNs 
Lateral compartment (levels II-V) 
- Total no. of LNs harvested 
- Total no. of positive LNs 
Overall (central + lateral compartments) 
- Total no. of LNs harvested 
- Total no. of positive LNs 
- ≤ 10 
- > 10 
- LN ratio (%)+ 
 
6.3 ± 5.8 
3.1 ± 2.9 
 
21.2 ± 15.1 
4.8 ± 3.0 
 
27.4 ± 17.9 
7.9 ± 7.2 
204 (77.3) 
60 (22.7) 
30.98 ± 22.02 
 
7.5 ± 6.6 
4.6 ± 5.2 
 
22.9 ± 16.8 
10.2 ± 5.6 
 
30.4 ± 22.4 
14.8 ± 8.4 
36 (34.3) 
69 (65.7) 
54.98 ± 25.12 
 
0.584 
0.046 
 
0.098 
<0.001 
 
0.195 
<0.001 
 
 
<0.001 
Mean size of largest positive LN (mm) 
- ≤ 3cm 
- > 3cm 
10.0 ± 7.4 
260 (98.5) 
4 (1.5) 
26.7 ± 11.2 
84 (80.0) 
21 (20.0) 
<0.001 
<0.001 
+LN ratio=(total number of positive LNs/ total number of LNs harvested) * 100 
Table 3. A comparison of postoperative stimulated thyroglobulin (sTg) levels, adjuvant 
treatment, response to therapy after ablation and locoregional recurrence between those without 
extranodal extension (ENE) (Group I) and with ENE (Group II) 
 Group I (n=264) Group II (n=105) p-value 
Postoperative stimulated Tg (sTg) 
(ng/mL) 
- Pre-ablation*  
- Post-ablation*  
 
 
43.51 ± 163.92 
8.20 ± 20.29 
 
 
150.57 ± 257.15 
40.56 ± 54.82 
 
 
<0.001 
<0.001 
Radioactive iodine dose (mCi) 82.70 ± 8.68 84.72 ± 72 0.082 
Central neck uptake on diagnostic 
whole body scan 
6 (2.3) 3 (2.9) 0.506 
External beam radiotherapy 9 (4.5) 7 (6.7) 0.405 
Response to therapy after ablation# 
- Excellent (sTg <1ng/mL) 
- Biochemical incomplete (sTg 
>10ng/mL) 
- Structural incomplete (structural 
or functional evidence of disease) 
- Indeterminate (sTg≥1ng/mL and 
≤10ng/mL) 
 
147 (55.7) 
46 (17.4) 
 
26 (9.8) 
 
45 (17.0) 
 
33 (31.4) 
46 (43.8) 
 
19 (18.1) 
 
7 (6.7) 
<0.001 
Follow-up period (months) 110.68 ± 51.43 121.55 ± 50.14 0.029 
Locoregional recurrence (LRR) 33 (12.5) 45 (42.9) <0.001 
Categorical variables are expressed as number (percentage) 
*2-3 months and 9-12 months after surgery, respectively 
#based on the 2015 ATA guidelines [8] and among those who received RAI ablation 
 
Table 4. Cox regression analyses of locoregional recurrence 
 Locoregional recurrence 
Univariate analysis Multivariate analysis^ Multivariate analysis# 
Variable HR 95%CI p-value HR 95%CI p-value HR 95%CI p-value 
Younger age 1.013 1.002 – 1.025 0.026 1.025 1.009 – 1.041 0.004 1.024 1.007 – 1.037 0.003 
Male sex 1.011 0.608 – 1.681 0.967       
Histological variants 1.353 0.938 – 1.950 0.105       
Larger tumor size 1.261 1.110 – 1.434 <0.001 1.226 1.021 – 1.417 0.029    
ETE 1.330 1.014 – 1.744 0.039 1.138 0.740 – 1.751 0.556    
Multicentricity 2.165  1.355 – 3.458 0.001 1.943 1.038 – 3.636 0.038 1.975 1.021 – 3.558 0.043 
Higher T stage 1.272 1.055 – 1.534 0.012    1.199 0.908 – 1.584 0.200 
No. of LNs harvested 0.995 0.983 – 1.007 0.426       
No. of positive LNs 1.037 1.013 – 1.062 0.003 1.011 0.978 – 1.046 0.514    
LNR* 1.025 1.016 – 1.034 <0.001    1.011 0.999 – 1.023 0.080 
Size of positive LN 1.599 1.340 – 1.909 <0.001 1.274 0.965 – 1.683 0.088 1.211 0.922 – 1.590 0.169 
Extra-nodal extension 4.404 2.807 – 6.909 <0.001 4.379 1.994 – 9.618 <0.001 4.193 2.398 – 7.332 0.001 
 Abbreviations:  ETE = extrathyroidal extension; ATA = American Thyroid Association; LN = lymph node; RAI = radioactive iodine; 
ERT = external beam radiotherapy 
^in model 1, age, primary tumor size, extrathyroidal extension, multifocality, number of positive LNs, size of largest LN and ENE 
were entered as co-variates. When age <45 years old was entered, the HR became 1.52 (1.002 – 2.653), p=0.042. 
#in model 2, age, multifocality, T stage, LN ratio, size of largest positive LN and ENE were entered as co-variates. When age <45 
years old was entered, the HR became 1.49 (1.001 – 2.551), p=0.049. 
*LNR = (total number of positive LNs/ total number of LNs harvested) * 100 
ATA risk stratification 1.076 0.612 – 1.889 0.800       
RAI dose 0.990 0.961 – 1.019 0.496       
ERT 0.548 0.173 – 1.738 0.307       
